IS7058A - Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf - Google Patents

Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf

Info

Publication number
IS7058A
IS7058A IS7058A IS7058A IS7058A IS 7058 A IS7058 A IS 7058A IS 7058 A IS7058 A IS 7058A IS 7058 A IS7058 A IS 7058A IS 7058 A IS7058 A IS 7058A
Authority
IS
Iceland
Prior art keywords
ethoxy
phenyl
butoxycarbonylaminophenyl
tert
methanesulfonylloxyphenyl
Prior art date
Application number
IS7058A
Other languages
English (en)
Inventor
Öhman Peter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7058A publication Critical patent/IS7058A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
IS7058A 2001-06-01 2003-11-28 Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf IS7058A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101980A SE0101980D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
PCT/SE2002/001038 WO2002096402A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug

Publications (1)

Publication Number Publication Date
IS7058A true IS7058A (is) 2003-11-28

Family

ID=20284362

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7058A IS7058A (is) 2001-06-01 2003-11-28 Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf

Country Status (25)

Country Link
US (1) US20040152771A1 (is)
EP (2) EP1666034A1 (is)
JP (1) JP2004532864A (is)
KR (1) KR20040008202A (is)
CN (1) CN1535144A (is)
AT (1) ATE336993T1 (is)
BR (1) BR0210128A (is)
CA (1) CA2448643A1 (is)
CO (1) CO5540375A2 (is)
CZ (1) CZ20033234A3 (is)
DE (1) DE60214185T2 (is)
EE (1) EE200300584A (is)
ES (1) ES2269686T3 (is)
HK (1) HK1062813A1 (is)
HU (1) HUP0400946A3 (is)
IL (1) IL159033A0 (is)
IS (1) IS7058A (is)
MX (1) MXPA03011005A (is)
NO (1) NO20035237D0 (is)
PL (1) PL367891A1 (is)
RU (1) RU2003136154A (is)
SE (1) SE0101980D0 (is)
SK (1) SK14702003A3 (is)
WO (1) WO2002096402A1 (is)
ZA (1) ZA200309264B (is)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
DK1145717T3 (da) * 2000-04-13 2004-08-02 Pfizer Prod Inc Synergistisk virkning af glyburid og milrinon

Also Published As

Publication number Publication date
BR0210128A (pt) 2004-06-08
ATE336993T1 (de) 2006-09-15
SE0101980D0 (sv) 2001-06-01
JP2004532864A (ja) 2004-10-28
HK1062813A1 (en) 2004-11-26
MXPA03011005A (es) 2004-02-27
WO2002096402A1 (en) 2002-12-05
EE200300584A (et) 2004-02-16
SK14702003A3 (sk) 2004-09-08
NO20035237D0 (no) 2003-11-25
ZA200309264B (en) 2005-02-28
CZ20033234A3 (cs) 2004-12-15
DE60214185D1 (en) 2006-10-05
EP1404309A1 (en) 2004-04-07
IL159033A0 (en) 2004-05-12
CN1535144A (zh) 2004-10-06
EP1666034A1 (en) 2006-06-07
KR20040008202A (ko) 2004-01-28
DE60214185T2 (de) 2007-07-19
CO5540375A2 (es) 2005-07-29
RU2003136154A (ru) 2005-02-10
HUP0400946A3 (en) 2007-11-28
US20040152771A1 (en) 2004-08-05
HUP0400946A2 (hu) 2004-08-30
PL367891A1 (en) 2005-03-07
ES2269686T3 (es) 2007-04-01
CA2448643A1 (en) 2002-12-05
EP1404309B1 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
HK1090294A1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4- oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate ;
BR9910913A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina
NO20022591D0 (no) Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre
BR0207509A (pt) Pirazolilpirimidinas
IS7058A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf
PE20070612A1 (es) Nuevos inhibidores de cisteina proteasas
IL172633A0 (en) Amine salts of (-)-2-{[2-(4-hydroxyphenyl) ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}
SE0101982D0 (sv) Pharmaceutical combination
SE0101981D0 (sv) Pharmaceutical combination
IS8234A (is) Kalíum- eða natríumsalt (-)-2-{[2-(4-hýdroxýfenýl)etýl]þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}fenýl]própansýru og notkun þeirra í læknisfræði
HUP0303027A2 (hu) Új benzoil-guanidin só és alkalmazása gyógyszerkészítmény előállítására
PE20090807A1 (es) Sulfonamidas substituidas, proceso para su preparacion y composicion farmaceutica de las mismas
ATE348605T1 (de) Stabilisierte formulierungen von 6-hydroxy-3-(4- (2-(piperidin-1-yl)ethoxy)phenoxy)-2-(4- methoxyphenyl)benzo(b)thiophen und deren salze
DE60310896D1 (de) PHARMAZEUTISCHE ZUBEREITUNGEN ENTHALTEND NANOPARTIKEL VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANSULPHONYL-PHENYL)-PYRAZOLOi1,5-BöPYRIDAZIN
AU2002254631A1 (en) Enantiomers of n-((2'-(((4,5-dimethyl-3-isoxazolyl) amino)sulfonyl)-4-(2-oxazolyl)(1,1'-biphenyl)-2-yl)methyl)-n,3,3-trimethylbutanamide
AR038306A1 (es) Composicion farmaceutica dispersable oralmente de 2-({2-metoxi-2-[(3-trifluorometil)fenil]etil}amino)etil-4-(2-{[2-(9h-fluoren-9-il)acetil]amino}etil)benzoato
DE60142063D1 (de) (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propion säureisopropylester, dessen herstellung und dessen verwendung